To improve the effectiveness of herpes simplex virus (HSV) thymidine kinase/ganciclovir (HSV-tk/GCV) suicide gene therapy, the replication-defective HSV vector TOIkB expressing both HSV-TK and a mutant form of the NF-kB inhibitor IkBa (IkBaM) was developed. TOIkB was constructed by recombining the IkBaM gene into the U L 41 locus of a replication-defective lacZ expression vector, TOZ.1. Expression of IkBaM was confirmed by Western blotting, and the ability of the mutant protein to inhibit NF-kB nuclear translocation was examined by electrophoretic mobility shift assay. In human glioblastoma U-87MG cells, the p50/p50 dimer of NF-kB was already translocated to the nucleus without receptor-dependent signaling by TNF-a. Following infection with TOIkB, nuclear translocation of NF-kB in U-87MG cells was significantly inhibited and caspase-3 activity increased compared with TOZ.1-infected cells. The cytotoxicity of TOIkB for U-87MG cells was investigated by colorimetric MTT assay. At an MOI of 3, TOIkB infection killed 85% of the cells compared to 20% killed by TOZ.1 infection. In the presence of GCV, these numbers increased to 95-100% for TOIkB and 80-85% for TOZ.1. TOIkB neurotoxicity measured on cultured murine neurons was relatively low and similar to that of TOZ.1. The survival of nude mice implanted into the brain with U-87MG tumor cells was markedly prolonged by intratumoral TOIkB injection and GCV administration. Survival of TOIkB þ GCV group was significantly longer (Po.02, Wilcoxon test) than for the control groups (TOZ.1 or TOIkB only, PBS or PBS þ GCV). These results suggest that IkBaM expression may be a safe enhancement of replication-defective HSV-based suicide gene therapy in vitro and in vivo.
D espite the use of combination treatments that may include conventional and fractionated radiation therapy, chemotherapy, and surgical resection, the prognosis for adult patients with malignant glioma, glioblastoma in particular, remains grim. 1 Gene therapy has the potential to change this situation. One anticancer gene therapy that has already been applied in clinical settings is the direct transfer of genes that activate prodrugs locally or induce apoptosis. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Although such ''suicide'' gene therapy has been successful to varying degrees in both preclinical and clinical studies, it is possible that ''cure'' rates can be improved through the use of multiple therapeutic genes.
We previously reported that enhanced tumor cell killing occurred upon coexpression of the herpes simplex virus (HSV) thymidine kinase (tk) and human TNF-a genes from an HSV-1-based vector in the presence of ganciclovir (GCV). 12 TNF-a activates the pathways of both apoptotic FADD and antiapoptotic NF-kB after binding to the TNF-a type 1 receptor. [13] [14] [15] By inhibiting the antiapoptotic NF-kB pathway with a nondegradable inhibitor of NF-kB, designated IkBaM, apoptotic pathways can become predominant resulting in increased cell death. [14] [15] Thus, IkBaM transduction can potentially enhance the efficacy of other tumoricidal treatments, including HSV-TK/GCV suicide gene therapy alone or in combination with TNF-a. On the other hand, it is possible that accelerated apoptosis of transduced cells limits the vector-dependent production of therapeutic agents such as HSV-TK-activated GCV that mediate the killing of neighboring untransduced cells by the so-called ''bystander effect.''
The Rel/NF-kB family of transcription factors plays important roles in immune and stress responses, inflammation, and apoptosis, and can regulate the expression of numerous cellular and viral genes. [16] [17] [18] [19] The NF-kB activity is composed of homodimers (p50/p50) or heterodimers (p50/p65) of related proteins that share a conserved DNA-binding and dimerization domain called the Rel homology domain. In most cell types, NF-kB is sequestered in the cytoplasm in complexes with inhibitory proteins called IkBa, IkBb, and IkBe. In response to diverse stimuli, including inflammatory cytokines, mitogens, bacterial lipopolysaccharide (LPS), and certain viral products, active NF-kB is released and translocated to the nucleus as a result of proteolytic degradation of the IkB proteins. Phosphorylation of IkBs on Ser-32 and Ser-36 targets these molecules for degradation by the ubiquitin-26S proteasome pathway. Mutations in the phosphorylation sites inhibits IkBa degradation and thus have a dominant-negative effect preventing activation on NF-kB activation.
In this study, the effectiveness of treating malignant cells with a replication-defective HSV-1 vector termed TOIkB, expressing HSV-TK along with the IkBa phosphorylation mutant IkBaM, was assessed in the presence and absence of GCV. Evidence is presented from cell culture experiments and in vivo experiments that the efficacy of HSV-TK suicide gene therapy can be moderately increased by cotransduction with IkBaM and that this codelivery system is relatively safe for neurons.
Materials and methods

Cell culture and virus production
Vero African Green Monkey kidney cells (CCL81, ATCC, Rockville, MD) and Vero-derived 7B cells 20 were maintained in minimum essential medium (MEM, Gibco-BRL, Gaithersburg, MD) supplemented with glutamine, antibiotics (PSN; Gibco-BRL), and 10% fetal bovine serum (FBS) (LTI, Gaithersburg, MD). U-87MG human glioblastoma cells (HTB-14, ATCC) were maintained in Dulbecco's MEM supplemented with glutamine, antibiotics, and 10% FBS.
HSV-1 stocks were prepared by infecting 7B cells, which supply the ICP4 and ICP27 proteins in trans, at a multiplicity of 0.03. Infected cells were harvested when a 100% cytopathic effect was evident and subjected to three cycles of freeze-thawing (À801C/371C) and a single burst of sonication. Virus was separated from cell debris by centrifugation and purified away from free protein and membrane particles by density gradient centrifugation (OptiPrep, Gibco-BRL). Virus stocks were aliquoted into 2 ml cryogenic tubes (Corning Glass Works, Corning, NY) and stored at À801C. Final titers averaged 5 Â 10 7 -5 Â 10 8 PFU/ml.
Construction of plasmids and recombinant vectors
Plasmids were isolated and grown in Escherichia coli strain DH5a (Gibco-BRL). Plasmid-transformed bacteria were selected on YT agar plates (YT is 5 g of yeast extract, 5 g of NaCl, and 8 g of bacto-tryptone per liter of distilled water, pH 7.0) containing 150 mg/ml ampicillin (Sigma, St Louis, MO) and grown in 2 Â YT broth containing 150 mg/ml ampicillin. Plasmid p41-IkB contains a human IkBaM cDNA expression cassette flanked on both sides by HSV U L 41 sequences. 20 IkBaM cDNA (a gift from Dr Inder Verma, Salk Institute, CA) [13] [14] [15] was under transcriptional control of the HSV-1 ICP0 immediate early (IE) promoter (ICP0p, Fig 1) . The p41-IkB plasmid was used to recombine the human IkBaM expression cassette into the U L 41 locus of replication-defective viral vector TOZ.1 21 using a previously described procedure. 20 Insertion of the expression cassette was confirmed by Southern blotting. The new vector (TOIkB) was purified by three rounds of limiting dilution. Both TOIkB and parental vector TOZ.1 were deficient for the HSV genes ICP4, ICP22, ICP27, U L 24, and U L 41. TOZ.1 contained a lacZ expression cassette in U L 41, [21] [22] [23] and both vectors had the early promoter of the resident thymidine kinase gene replaced by the IE ICP4 promoter, which enabled expression of the tk gene as an IE gene but disrupted the overlapping U L 24 gene.
Southern blotting
Bam HI-digested viral DNAs were electophoresed on 1% agarose gels in TAE buffer, blotted to Nytran membrane (Hybond-N þ , Amersham, UK), and crosslinked in a UV Stratalinker 2400 (Stratagene, La Jolla, CA). The membranes were hybridized with chemiluminescent probes specific for the human IkBaM gene (1.2-kbp EcoRI-EcoRI-coding fragment) and the HSV-1 U L 41 gene (0.9-kbp KpnI-EcoRV fragment). After washing, hybridization was detected with CDP-Star (AlkPhos direct RPN3680, Amersham, Buckinghamshire, UK).
Western blotting
1 Â 10 6 U-87MG cells were infected with TOIkB or TOZ.1 at an MOI of 3.0 and incubated for 24 h at 371C in 5% CO 2 . The infected cells were washed with PBS, lysed with lysis buffer (20 mM Tris (pH 7.2), 0.1% SDS, 0.1% Triton X-100, 1 mM PMSF, 10 mg/ml leupeptin), sonicated, and the protein concentrations of the lysates were determined. In all, 40 mg of each lysate was resuspended in Laemmli buffer and the samples were electrophoresed on 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membrane, probed with a rabbit anti-IkBa polyclonal antibody (sc-203, Santa Cruz Biotechnology, Santa Cruz, CA), and the reactive material was visualized by ECL (Amersham, Buckingham, UK).
Electrophoretic mobility shift assay
Five different treatments were tested on cultures of U-87MG cells: (1) no treatment, (2) addition of 10 ng/ml purified recombinant TNF-a (Genzyme, Cambridge, MA) to the culture medium, (3) TOIkB infection (MOI 3.0), (4) Combined therapy with TK/GCV and IkBaM S Moriuchi et al TOZ.1 infection (MOI 3.0), and (5) TOIkB infection (MOI 3.0) with addition of TNF-a. At 15 hours after infection and/or addition of TNF-a, nuclear extracts were prepared by the method of Dignam et al. 24 Electrophoretic mobility shift assays (EMSAs) were performed as described 25 using nuclear extract at 5 mg protein/well. Binding reactions were performed by incubating nuclear extracts with a 32 P-labeled double-stranded oligonucleotide probe containing an NF-kB-binding site purchased from Promega (Madison, WI). NF-kB complexes were separated from unbound probe by native 4% polyacrylamide gel electrophoresis and visualized by autoradiography. The specificity of NF-kB binding was determined by competition with cold probes. For supershift assays, 4 mg of anti-p65 NF-kB monoclonal antibody (sc-109x, Santa Cruz) was used.
In vitro cytotoxicity assays
The toxicity of TOIkB for U-87MG human glioblastoma cells was examined by standard MTT assay. 26 Cells were infected in suspension for 1 hour at an MOI of 3 and dispensed into 96-well flat-bottom microtiter plates (Becton Dickinson, Franklin Lakes, NJ) at a concentration of 1 Â 10 4 cells in 100 ml. For the experiment with defined infection ratios, U-87MG cells were infected at an MOI of 10 (100% infection), washed with 0.1 M glycine (pH 3.0) to remove extracellular virus, and mixed with uninfected U-87MG cells. The cells were incubated for several days with or without GCV (10 mg/ml) at 371C in 5% CO 2 . On days 2, 4, 6, and 8 postinfection, 25 ml 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) solution (5 mg/ml, Sigma Chemicals) was added to each well and incubation at 371C in 5% CO 2 was continued for 30 minutes. Supernatants were removed and 100 ml dimethylsulfoxide was added to each well. After another 30 minutes incubation, absorbances were read by an EL312e plate reader equipped with a 570 nm filter (Biotek Instruments, Winooski, VT).
Caspase-3 colorimetric assay
To determine whether TOIkB could induce apoptosis in U-87MG cells, the enzymatic activity of the caspase-3 6 U-87MG cells were infected with TOIkB or TOZ.1 in suspension for 1 hour at an MOI of 3.0 and plated in 6 cm dishes in triplicate. Cells were incubated for 24 hours with or without GCV (10 mg/ml). Cells were scraped and collected by centrifugation. Pellets were lysed and the assay performed according to the manufacturer's instructions.
Primary neuronal culture and neurotoxicity assay for TOIkB
Primary cultures of murine cortical neurons were prepared from 17-day-old embryonic mice (Nippon SLC). Brains were dissected free of meninges and incubated with trypsin (Difco) and DNase I (Sigma) at 371C for 15 minutes. Cortices were dissociated mechanically using a pipet and resuspended in serum-free B27/ Neurobasal medium (Gibco). 27 Cells were plated at a density of 1.0 Â 10 5 /cm 2 in 96-well plates precoated with polyethylenimine. 28, 29 Cultures were infected with TOIkB or TOZ.1 at an MOI of 0.5 in the presence or absence of GCV (10 mg/ml). The infected cultures were maintained in serum-free B27/Neurobasal medium in a humidified atmosphere (5% CO 2 /95% air) at 371C for 4 days, and examined by MTT assay.
In vivo tumor implantation and treatment
All tumor experiments were carried out with female athymic nude mice (BALB/c-nu Slc), 7 weeks of age. Intracerebral tumors were generated by stereotactic injection of 1 Â 10 5 U-87MG cells into the right frontal lobe (3 mm to the right of the midline, 1 mm caudal from bregma, 3 mm in depth from the dura. 12, 35 Tumors were treated by injecting 1 Â 10 6 PFU of vector or PBS in the same location 3 days after tumor implantation. In total, 50 mg/kg GCV were administered i.p. every 24 hours for 7 days. 12, 35 Animals were monitored until death. Treatment groups consisted of 5-7 animals assigned randomly.
Results
TOIkB vector construction
A replication-defective genomic HSV-1 vector was constructed for coexpression of HSV-TK and IkBaM, a degradation-resistant mutant form of the NF-kB inhibitor IkBa, by recombining an IkBaM expression cassette into the U L 41 locus of a previously described HSV vector, TOZ.1 (Fig 1a, TOIkB) . TOZ.1 had the following features: (i) it was deleted for two essential and one nonessential IE gene (ICP4, ICP22, ICP27) and was therefore highly defective for early (E) and late (L) gene expression and incapable of productive infection; (ii) it contained a lacZ expression cassette interrupting and thereby inactivating the U L 41 gene encoding the host protein synthesis shut-off function; and (iii) it had a modified tk (U L 23) locus in which the native E promoter (as well as the U L 24 gene encoded on the opposite DNA strand) was replaced by the ICP4 IE promoter (ICP4p) in order to express TK as an IE gene product. 21 We and others have previously reported that combined IE gene deficiencies such as those of TOZ.1 substantially reduce the undesirable cytotoxicity of wild-type HSV-1 and mutant vectors deleted for single IE genes, [20] [21] [22] [23] which results in extended transgene expression. 20 The IkBaM expression cassette used for recombination consisted of a human IkBaM cDNA between a copy of the HSV-1 ICP0 IE promoter and the polyadenylation region from U L 41 and was surrounded by flanking sequences from the U L 41 locus in a plasmid background. The IkBaM cassette was introduced in place of the resident lacZ cassette of TOZ.1 by homologous recombination using an efficient protocol described previously, 20 and the structure of the final TOIkB isolate was confirmed by Southern blot analysis (Fig 1b, c) .
IkBaM expression in TOIkB-infected U-87MG human glioblastoma cells was tested by Western blotting 24 hours after infection compared to TOZ.1-infected cells and cells incubated for 24 hours with recombinant human TNF-a (10 ng/ml). IkBaM was observed as a prominent band only in the TOIkB sample while IkBa and phosphorylated IkBa were detected in all four samples (Fig 2) . At 24 hours, the amount of phosphorylated IkBa appeared to be similar in TNF-a-treated and untreated or virusinfected cells, suggesting the re-establishment of an equilibrium between IkBa and its labile form at this time.
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Bioactivity of IkBaM produced in TOIkB-infected U-87MG cells After TNF-a binding to the TNF-a type 1 receptor, both the antiapoptotic NF-kB and apoptotic FADD pathways are activated. If inhibition of NF-kB translocation to the nucleus occurred as a consequence of IkBaM expression, the apoptotic FADD pathway would become predominant and cause apoptosis. [13] [14] [15] The status of NF-kB in the nucleus 15 hours after infection or addition of TNF-a to Combined therapy with TK/GCV and IkBaM S Moriuchi et al the media was investigated by EMSA on nuclear extracts 24, 25 (Fig 3) . Untreated U-87MG cells already contained nuclear NF-kB in the p50/p50 homodimeric form (lane 2), but incubation with TNF-a increased the total amount of translocated NF-kB, specifically the p50/p65 heterodimeric form (lane 3). In contrast, TOIkB-infected as well as TOIkB-infected, TNF-treated U-87MG cells showed highly reduced nuclear levels of NF-kB (lanes 5, 6), whereas infection with control virus TOZ.1 had essentially no effect (lane 4). The observed bands were specific for the NF-kB probe as they were not seen when the reaction with extract from TNF-a-treated cells was carried out in the presence of 100-fold excess unlabeled NF-kB probe (lane 7), while 100-fold excess unlabeled Oct-1 probe left the signals largely unchanged (lane 8). Incubation of the same extract with antibodies to NF-kB p65 (lane 9) created a supershift band while the p65/p50 band was no longer observed, confirming that the upper band in lanes 3 and 8 contained NF-kB p65. Together, these results showed that virally expressed IkBaM could inhibit default nuclear accumulation of NF-kB in U-87MG cells as well as additional NF-kB nuclear localization in response to TNF-a treatment.
Killing of U-87MG cells in vitro following TOIkB infection
To determine whether vector-directed production of IkBaM could promote cell killing with or without external mediators, U-87MG cells were infected with TOIkB or parental vector TOZ.1 (MOI ¼ 3), the cells maintained for 4 days in the presence or absence of GCV, and the viability was measured by standard MTT assay (Fig 4a) . TOIkB alone killed 85% of the cells, which increased to 100% in the presence of GCV. By comparison, TOZ.1 alone was largely ineffective, but addition of GCV to the media resulted in 85% killing. Addition of TNF-a had relatively minor effects on both TOIkB-and controlinfected cultures with or without GCV although some toxicity was observed for uninfected cells.
To obtain a more accurate measure of viral cytotoxicity and detect potential bystander effects, cell survival was determined in mixed cultures containing different ratios of infected (MOI ¼ 10) and uninfected cells; infected cells were acid-treated to remove extracellular virus before they were mixed with uninfected cells. Without the addition of uninfected cells (100% infection rate; Fig 4b) , TOIkB infection (MOI ¼ 10) killed all cells, whereas approximately 35% of the cells in the corresponding TOZ.1-infected culture survived. Thus at this high MOI, TOIkB was 100% cytotoxic while TOZ.1 killed at least two of every three cells. At a 50% infection rate (50% uninfected cells, 50% cells infected at MOI ¼ 10), approximately 35% of the cells or two out of every three infected cells died in the TOZ.1 culture, suggesting that no widespread killing of uninfected cells occurred and hence that TOZ.1 infection did not mediate a substantial bystander effect in the absence of GCV. While relatively more cell death was seen at 10 and 20% TOZ.1 infection rates (20-25% cell death compared to predicted values of 7-14% in the absence of bystander effects), these deviations were not substantially outside the range of variability of the assay. Deviations from the predicted values were also observed for cultures containing TOIkB-infected cells. When 50% of the cells in these cultures were infected, approximately 80% of the culture was killed. Likewise, 40% cell death was observed in cultures containing 20% TOIkB-infected cells and roughly 20% death in cultures with 10% infected cells. Thus in this case, the differences between infection rates and cell death were more consistent, raising the possibility of a small, but genuine bystander effect mediated by TOIkB-infected cells. In the presence of GCV, both vectors mediated a significant bystander effect as almost invariably a greater fraction of the cells died than were infected by virus. Oddly, complete killing of TOZ.1-infected cultures in the presence of GCV was not observed in these experiments, even in the absence of added uninfected cells. Cell killing by TOIkB infection with exposure to GCV was more efficient, as Combined therapy with TK/GCV and IkBaM S Moriuchi et al also observed in Figure 4a , although not by a large margin. Overall, these results indicated that TOIkB was more toxic for cultured U-87MG cells than TOZ.1 and that in combination with GCV, TOIkB was somewhat more effective than TOZ.1 in eliminating U-87MG cells.
Apoptotic activity in TOIkB-infected cells
To determine if increased apoptotic activity could be observed in TOIkB-infected cells compared to TOZ.1-infected cells (MOI ¼ 3), caspase-3 activity was measured (Fig 5) . TOZ.1-infected cells incubated with GCV displayed greater activity (A 405 ¼ 0.140) than TOZ.1-infected cells without GCV or uninfected cells incubated with GCV (A 405 ¼ 0.080). However, the greatest increases in caspase activity were observed in TOIkB-infected cells with (A 405 ¼ 0.320) or without GCV incubation (A 405 ¼ 0.280). The differences between TOIkB-and TOZ.1-infected cells were statistically significant (Po.05, Student's t-test), indicating that vector-based IkBaM expression could induce enhanced apoptotic activity independent of HSV-TK/GCV-mediated cytotoxicity.
Neurotoxicity of TOIkB in vitro
Neurotoxicity of TOIkB was examined on cultured murine fetal neurons. Cultures were prepared from 14-day-old embryonic BALB/c mouse brains under serumfree conditions, infected with TOIkB or TOZ.1 (MOI ¼ 0.5), cultured for 4 days in the presence or absence of GCV, and examined by MTT assay. GCV displayed some toxicity after infection with either virus (Fig 6) , as anticipated since these cultures were not purified to the extent that they were free of dividing cells. However, no major differences in survival were observed between the two vectors in either the presence or absence of GCV; the perceived higher toxicity of TOIkB compared to TOZ.1 in the absence of GCV may also be attributed to culture impurity. Thus, these results Combined therapy with TK/GCV and IkBaM S Moriuchi et al suggested that IkBaM may not be significantly harmful to normal neuronal cells.
In vivo treatment experiments with TOIkB
The primary incentive to test our combination gene therapy against U87 MG tumors was the encouraging, albeit unexplained, observation earlier that vector-directed IkBaM expression could augment the killing by TKactivated GCV of U-87MG cells in vitro. U-87 MG cells (1 Â 10 5 ) were stereotactically implanted into athymic nude mice at a site where glioblastomas may develop naturally, the right frontal lobe of the brain. After 3 days, the mice were randomly divided into six groups and injected with PBS or virus (1 Â 10 6 PFU) using the same stereotactic coordinates as used earlier for tumor implantation. For practical reasons, vector application in this model was initially limited to a single injection. GCV was administered to selected groups by daily i.p. injection (1 mg) for a period of 7 days, starting at the day of vector application, and the animals were observed until death.
The results in Figure 7 readily suggest an increase in survival times for animals injected with TOIkB or TOZ.1 and treated with GCV. The median survival times for these groups were 21 and 17 days, respectively. Survival of TOIkB þ GCV group was significantly longer (Po.02, Wilcoxon test) than for the control groups (TOZ.1 or TOIkB only, PBS or PBS þ GCV), the mean survival times of which ranged from 14 and 16 days. However, only treatments involving TOIkB þ GCV were significantly different from the treatments using TOIkB (Po.02). The difference in survival times between TOIkB/GCV and TOZ.1/GCV groups was not statistically significant (P ¼ .0662, Wilcoxon test).
Discussion
It has been shown previously that suicide gene therapy can be an effective methodology for killing tumor cells in culture and in vivo. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] For example, the survival of rats implanted with tumor-generating 9L gliosarcoma cells was prolonged 1.5 times or more by HSV-tk/GCV therapy and some rats were cured completely. 5, [8] [9] [10] [11] However, the results of clinical trials indicate a need for greater efficacy. In a recent phase III trial, 124 glioblastoma patients were treated by intratumoral implantation of cells producing a retroviral vector expressing HSV-TK, and compared with 124 glioblastoma patients treated with conventional therapy. There was no benefits in patients with gene therapy. 30 The two central aspects of HSV-tk/GCV therapy that leave room for improvement are the transduction rate of the vectors and the bystander effect. The natural tropism of HSV for neuronal cells provides a rational approach toward the first issue and we have over the years developed a series of HSV vectors suitable for efficient delivery of HSV-tk and accessory transgenes to neurons. 20, 21 In our continuing efforts to assess different mechanisms for their potential to enhance the bystander effect, we have now tested the apoptosis-supporting activity of IkBaM, a stable negative regulator of the antiapoptotic NF-kB protein, alone and in conjunction with HSV-tk/GCV therapy.
Under normal conditions, NF-kB exists in the cytoplasm in an inactive form complexed with IkBa. In response to triggers such as TNF-a binding to the TNF-a receptor, IkBa is degraded and NF-kB released for translocation to the nucleus where it performs its various functions, including inhibition of the FADD apoptotic pathway by way of NF-kB-induced antiapoptotic proteins (bcl-2, cmyc, etc.). 19 As a stable derivative of IkBa, IkBaM prevents the nuclear translocation NF-kB and thus establishment of the antiapoptotic state. However, in some Combined therapy with TK/GCV and IkBaM S Moriuchi et al malignant tumor cells, NF-kB localizes to the nucleus independent of external stimuli. 19 Accordingly, these tumor cells may exist in a permanently antiapoptotic state. It has been reported that NF-kB activation serves as a principal mechanism for inducible resistance to chemotherapy 31 and the default nuclear localization of NF-kB in certain tumor cells is therefore a troubling characteristic. Our current study was based on the hypothesis that stable inhibition of NF-kB nuclear translocation in HSV-tk-transduced tumor cells could increase the efficacy of GCV-mediated tumor cell killing. In addition, we determined whether this mechanism could enhance the sensitivity of tumor cells to TNF-a.
U-87MG human glioblastoma cells were infected with the replication-defective HSV-1 recombinant vector TOIkB expressing IkBaM along with HSV-TK, and cell survival was measured. Compared to the HSV-TK control vector TOZ.1, TOIkB infection at an MOI of 3 increased U-87MG cell death in the absence of added GCV or TNF-a. Furthermore, decreased cell survival was observed in mixed cultures of infected (MOI ¼ 10) and uninfected cells containing at least 20% infected cells. Caspase-3 activity was increased significantly by TOIkB compared to TOZ.1 infection, suggesting that inhibition of the default nuclear localization of NF-kB in these cells causes cell death by triggering apoptosis, either alone or perhaps in conjunction with the process of viral infection. Combination of virus-based IkBaM expression with the HSV-TK/GCV system further raised the level of cytotoxicity, accomplishing complete or nearly complete killing of U-87MG cell cultures at an MOI of 3 as well as at high infection rates (50-100%) in mixed cultures. Again, these levels exceeded those reached by the HSV-tk control vector TOZ.1 under the same conditions. Adenoviral delivery of IkBaM has been shown to suppress TNF-a-induced NF-kB activity in human head and neck carcinoma cells in culture and sensitize chemoresistant tumors in mice to apoptosis induced by TNF-a or a chemotherapeutic agent, resulting in tumor regression. 31 In our experiments, HSV vector-mediated delivery of IkBaM resulted in increased killing of human glioblastoma cells in the absence of external triggers of apoptosis, perhaps similar to the reported regression of head and neck tumors in SCID mice treated with the adenoviral IkBaM vector. 32 Most of the IE HSV proteins are cytotoxic, but only one of these, ICP0, is expressed by our vectors due to gene deletions affecting the others (ICP4, ICP22, and ICP27). ICP0 reportedly induces p53 and promotes the apoptotic pathway, 33 suggesting that IkBaM in our system may act by enhancing these ICP0 activities, thus effecting increased cell killing in the absence of external inducers of apoptosis. Likewise, HSV-TK/GCV has been reported to augment p53 accumulation, increase expression of the TNF-a type 1 receptor CD95 as well as FADD, and induce caspase 8 and apoptosis. 34 Thus in the presence of GCV, IkBaM may additionally sensitize TOIkB-infected cells to the apoptotic events triggered by HSV-TK-activated GCV. Since the interplay of IkBaM with the ICP0 and HSV-TK/GCV apoptotic pathways is limited to infected cells, clear effects of IkBaM on infected cultures are not expected at low infection rates. In fact, it is possible that accelerated death of infected cells reduces the HSV-TK/ GCV bystander effect by prematurely aborting the production of HSV-TK. At higher infection rates, however, the bystander effect plays an increasingly smaller role so that the apoptosis-enhancing activity of IkBaM may become increasingly evident. Our results in Figure 4b are consistent with this scenario.
The survival of animals implanted into the brain with U-87MG tumor cells was markedly prolonged by intratumoral TOIkB injection and GCV administration compared with the control groups (TOIkB, TOZ.1 PBS, or PBS þ GCV), but TOIkB þ GCV group was not significantly prolonged the survival from TOZ.1 þ GCV group. These results indicate that while IkBaM expression in transduced tumor cells enhances the efficacy of TK/ GCV therapy in vivo, the low infection rate achieved by local virus injection remains an obstacle. 12, 35 At the same time, the clear benefits of combination gene therapy involving HSV-TK observed here and elsewhere with different accessory genes, 12, 20, 35, 36 or with other modalities such as stereotactic radiation or chemotherapy, 37 raise the expectation that further gains toward successful therapy can be achieved by the inclusion of additional enhancing genes in the vector, a practical option given the ability of HSV vectors to accommodate multiple independently regulated transgenes. 20, 21 Neurotoxicity is a concern in any treatment for malignant glioma. This issue was examined by comparing the toxicities of TOIkB and TOZ.1 for murine fetal neurons in culture. At an MOI of 0.5, where approximately 20% of the cells are infected, TOZ.1 had no effect on cell viability while TOIkB reduced viability by some 20%. In the presence of GCV, the two vectors reduced cell viability by approximately 35 and 40%, respectively. These numbers do not take into account contamination of the neuron preparations with dividing cells. Unlike neurons, dividing cells are sensitive to HSV-TK/GCV, suggesting that our comparison of GCV-treated neuron cultures provided a more accurate estimate of the effect of IkBaM on neuron viability than the accompanying comparison of untreated cultures (Fig 6) . In this case, IkBaM appears to be less toxic for neurons than for U-87MG cells (see Fig 4b, 20% infection) , although the comparison is handicapped by the different experimental conditions of Figures 6 and 4b . It has been reported that transgene expression from replication-defective HSV vectors is attenuated in neurons by inhibition of nuclear translocation of viral ICP0, 38, 39 which would have the effect of reducing both the apoptosis-inducing activity of ICP0 and the enhancing activity of IkBaM, thus limiting TOIkB neurotoxicity.
In summary, IkBaM inhibits NF-kB nuclear translocation and thereby the expression of NF-kB-dependent antiapoptotic genes. Inhibition of the NF-kB pathway may enhance the efficacy of cancer chemotherapy and other proapoptotic treatments. Our nonreplicating recombinant HSV-1 vector TOIkB coexpressing HSV-TK and IkBaM was more effective in killing human glioblastoma U-87MG cells in the presence of GCV than a comparable HSV-TK vector both in vitro and in vivo. Furthermore, TOIkB appeared less toxic for neurons than for U-87MG tumor cells. TOIkB-infected U-87MG cells showed a reduction in the default nuclear localization of NF-kB, indicating that TOIkB may promote enhanced tumor cell killing by facilitating ICP0-and HSV-TK/ GCV-induced apoptosis.
